ArticleAnalytical and bioanalytical chemistry2022
Nanoceria-based lateral flow immunoassay for hydrogen peroxide-free colorimetric biosensing for C-reactive protein.
Article in Analytical and bioanalytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 35 citations in OpenAlex.
- Overcoming HRP/TMB/HBiosensors · 2026Article
- Oxidase activity-enhanced manganese (III) oxide nanozyme grown in dendritic mesoporous silica nanoparticles for sensitive lateral flow immunoassay of C-reactive protein.Mikrochimica acta · 2026Article
- Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications.Materials today. Bio · 2025Article
- Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C.Biosensors · 2025Article
- Nanozyme-based visual diagnosis and therapeutics for myocardial infarction: The application and strategy.Journal of advanced research · 2025Review
- A Visual Distance-Based Capillary Immunoassay Using Biomimetic Polymer Nanoparticles for Highly Sensitive and Specific C-Reactive Protein Quantification.International journal of molecular sciences · 2024Article
- Article
- Post-Assay Chemical Enhancement for Highly Sensitive Lateral Flow Immunoassays: A Critical Review.Biosensors · 2023Review
- Diagnoses Based on C-Reactive Protein Point-of-Care Tests.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
During the recent several decades, lateral flow immunoassay (LFIA) constructed with gold nanoparticle (AuNP) has been widely utilized to conveniently detect target analyte. However, AuNP-based LFIA has limitations, such as limited detection sensitivity and quantification capability. Herein, to overcome these constraints, we have developed cerium oxide nanoparticle (nanoceria)-based LFIA for C-reactive protein (CRP) detection in human serum samples. It was fabricated with nanoceria, a notable nanozyme that shows an oxidase activity to quickly oxidize organic substrate, such as 3,3',5,5'-tetramethylbenzidine (TMB), to produce colored product without any oxidizing agent (e.g., hydrogen peroxide), which is advantageous for realizing point-of-care testing (POCT) applications. By employing human blood serum spiked with CRP, the nanoceria-based LFIA showed two blue-colored lines on the test and control region within 3 min via TMB oxidation, by the captured nanoceria through antigen-antibody interaction. The produced blue-colored lines were distinguished by naked eyes and quantitated with real images acquired by a conventional smartphone with the ImageJ software. With this strategy, target CRP was specifically determined down to 117 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.